These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32982484)

  • 1. Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN
    Pessoa B; Melo-Beirão J; Meireles A; Menéres P
    Int Med Case Rep J; 2020; 13():437-448. PubMed ID: 32982484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
    Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
    Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
    Schmit-Eilenberger VK
    Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
    Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
    Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
    Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J
    Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
    Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R;
    Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scleral fixation of fluocinolone acetonide implant.
    Tabandeh H; Rezaei K
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100775. PubMed ID: 32577584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes.
    Estebainha R; Goldhardt R; Falcão M
    Curr Ophthalmol Rep; 2020 Mar; 8(1):1-10. PubMed ID: 32346496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 14. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
    Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema.
    Coney JM
    Int Med Case Rep J; 2019; 12():161-169. PubMed ID: 31213929
    [No Abstract]   [Full Text] [Related]  

  • 16. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant.
    Pessoa B; Ferreira A; Leite J; Figueira J; Meireles A; Beirão JM
    Ophthalmic Res; 2021; 64(4):639-647. PubMed ID: 33601389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
    Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
    Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema.
    Augustin AJ; Bopp S; Fechner M; Holz FG; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer MS; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H
    Eur J Ophthalmol; 2021 May; ():11206721211014728. PubMed ID: 33947233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILUVIEN
    Teixeira C; Pessoa B; Ruão M; Sousa JPC; Penas S; Silva R; Carneiro Â; Meireles A
    Eur J Ophthalmol; 2023 Nov; ():11206721231217525. PubMed ID: 38013451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.